Gα13 Negatively Controls Osteoclastogenesis Through Inhibition of the Akt-GSK3β-NFATc1 Signalling Pathway

Mengrui Wu,Wei Chen,Yun Lu,Guochun Zhu,Liang Hao,Yi-Ping Li
DOI: https://doi.org/10.1038/ncomms13700
IF: 16.6
2017-01-01
Nature Communications
Abstract:Many positive signalling pathways of osteoclastogenesis have been characterized, but negative signalling pathways are less well studied. Here we show by microarray and RNAi that guanine nucleotide-binding protein subunit α13 (Gα13) is a negative regulator of osteoclastogenesis. Osteoclast-lineage-specific Gna13 conditional knockout mice have a severe osteoporosis phenotype. Gna13 -deficiency triggers a drastic increase in both osteoclast number and activity (hyper-activation), mechanistically through decreased RhoA activity and enhanced Akt/GSK3β/NFATc1 signalling. Consistently, Akt inhibition or RhoA activation rescues hyper-activation of Gna13 -deficient osteoclasts, and RhoA inhibition mimics the osteoclast hyperactivation resulting from Gna13 -deficiency. Notably, Gα13 gain-of-function inhibits Akt activation and osteoclastogenesis, and protects mice from pathological bone loss in disease models. Collectively, we reveal that Gα13 is a master endogenous negative switch for osteoclastogenesis through regulation of the RhoA/Akt/GSK3β/NFATc1 signalling pathway, and that manipulating Gα13 activity might be a therapeutic strategy for bone diseases.
What problem does this paper attempt to address?